We have previously published protocols for high-throughput IgG reformatting and expression, that enable rapid reformatting of phage-displayed antibody Fab fragments into a single dual expression vector for full IgG expression in Expi293F cells (Chen et al. Nucleic Acids Res 42:e26, 2014; Chen et al. Methods in Molecular Biology, vol 1701, 2018). However, when working with phage clones from a naïve library containing highly diverse N-terminal sequences, where the 5' PCR primers bind, the PCR step can become cumbersome. To overcome this limitation, we have investigated and found that the C-terminal 7 amino acid residues of the human antibody VH1 secretion signal can be replaced with those from ompA or pelB bacterial signals to form hybrid signal sequences that can drive strong IgG expression in Expi293F cells. The use of such hybrid signals allows any Fab fragment in the library to be amplified and cloned into the IgG expression vector using only a single 5' PCR primer targeting the bacterial secretion signal of the light or heavy chain, thus dramatically simplifying the IgG reformatting workflow.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-0716-3381-6_23DOI Listing

Publication Analysis

Top Keywords

igg reformatting
12
igg expression
12
high-throughput igg
8
reformatting expression
8
expression vector
8
expression expi293f
8
expi293f cells
8
secretion signal
8
expression
6
igg
5

Similar Publications

Restructuring Biologically Assembled Binding Protein-Biopolymer Conjugates toward Advanced Materials.

ACS Appl Mater Interfaces

December 2024

Centre for Cell Factories and Biopolymers, Griffith Institute for Biomedicine and Glycomics, Griffith University, Nathan, QLD 4111, Australia.

Bacterial cell factories have been successfully engineered to efficiently assemble spherical polyhydroxybutyrate inclusions coated with functional proteins of interest. In these submicrometer-sized core-shell assemblies, proteins are bioconjugated to the polymer core, enabling bioengineering for uses as bioseparation resins, enzyme carriers, diagnostic reagents, and particulate vaccines. Here, we explore whether these functional protein-polymer assemblies could be restructured via dissolution and subsequent precipitation while retaining the functionality of the conjugated protein.

View Article and Find Full Text PDF
Article Synopsis
  • * One selective antibody fragment, C12, was developed into a full IgG and was shown to bind effectively to ADAM17, preventing the activation of cancer cell pathways by inhibiting EGFR phosphorylation.
  • * C12 demonstrated anti-tumor effects by reducing the viability of various EGFR-expressing cancer cells and inhibiting tumor growth in an ovarian cancer model, with imaging confirming its presence at tumor sites.
View Article and Find Full Text PDF

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.

Cancer Immunol Immunother

October 2024

Center for Translational Immunology, University Medical Center, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.

Recent advances in cancer immunotherapy, particularly the success of immune checkpoint inhibitors, have reignited interest in targeted monoclonal antibodies for immunotherapy. Antibody therapies aim to minimize on-target, off-tumor toxicity by targeting antigens overexpressed on tumor cells but not on healthy cells. Despite considerable efforts, some therapeutic antibodies have been linked to dose-limiting side effects.

View Article and Find Full Text PDF

EGFR plays an essential role in cellular signaling pathways that regulate cell growth, proliferation, and survival and is often dysregulated in cancer. Several monoclonal IgG antibodies have been clinically tested over the years, which exert their function via blocking the ligand binding domain (thereby inhibiting downstream signaling) and inducing Fc-related effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). However, these IgG antibodies do not optimally recruit neutrophils, which are the most abundant white blood cell population in humans.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists are finding new ways to help immunotherapy work better by targeting a protein called A2A receptor (A2AR) that can make cancer stronger.
  • They discovered a special antibody called TB206-001 that can block A2AR and potentially help the body's immune system fight tumors more effectively.
  • TB206-001 has shown strong results in lab tests and could be used in future cancer treatments that combine different therapies for better results.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!